Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA acting CIO to depart

Executive Summary

FDA Acting Chief Information Officer Fred Farmer is leaving to return to a career in the private sector, effective July 22. Farmer assumed the role of acting CIO following the departure of CIO Jim Rinaldi last year (1"The Pink Sheet" Aug. 1, 2005, In Brief). FDA Associate Commissioner for Management and CFO Kathleen Heuer will assume the role of acting CIO as the agency completes its search for a permanent replacement...

You may also be interested in...



FDA information technology

FDA Information Technology Program Director Fred Farmer will become acting chief information officer Aug. 1 until a permanent replacement is found for departing CIO Jim Rinaldi. Rinaldi has accepted the CIO position with NASA's Jet Propulsion Laboratory; he became FDA's CIO in December 2002 ( 1"The Pink Sheet" Jan. 13, 2003, In Brief)...

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

UsernamePublicRestriction

Register

PS047357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel